A retrospective analysis of pharmacokinetic-pharmacodynamic parameters as indicators of the clinical efficacy of ceftizoxime

被引:0
|
作者
Sánchez-Navarro, A [1 ]
Colino, CI [1 ]
Recio, MMS [1 ]
机构
[1] Univ Salamanca, Fac Farm, Dept Farm & Tecnol Farmaceut, E-37007 Salamanca, Spain
关键词
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: To analyse the relationship between a series of estimated pharmacokinetic-pharmacodynamic parameters and the reported efficacy of ceftizoxime. Design: Retrospective literature search and analysis using different correlation models. Methods: The following parameters were calculated for each group of patients included in the study from the simulated plasma concentration curves corresponding to the dosage regimen administered: (i) peak concentration at steady state divided by the minimum inhibitory concentration (Cmax (SS)/MIC); (ii) the time that the plasma drug concentration exceeded the MIC scaled to 24 hours at steady state [(t(ss))(24h) > MIC]; (iii) the total area under the concentration-time curve over 24 hours at steady state divided by the MIC [(AUC(SS))(24h)/MIC]; and (iv) the AUC at steady state for the period of time that the concentration is above the MIC over a period of 24 hours divided by the MIC [(AUIC(SS))24h] A univariate correlation analysis was performed considering efficacy [rate (%) of clinical cure or bacterial eradication] as the dependent variable and the pharmacokinetic-pharmacodynamic parameter as the independent variable, using linear and nonlinear models. Results: (tss)24h > MIC was the only parameter that was statistically correlated with efficacy, the linear model being the best choice among the 4 relationship approaches tested. A biased frequency distribution of reported efficacy data constricts the correlation analysis to a narrow range of efficacy and hinders interpretation of the results. Conclusions: The reporting of cases with low efficacy rates as well as those with high efficacy rates, including information on patient idiosyncrasies and the infecting organisms, would be of great help in performing retrospective analyses of the use of antimicrobial agents, leading to the optimisation of therapy with this type of drug in clinical practice.
引用
收藏
页码:125 / 134
页数:10
相关论文
共 50 条
  • [31] Uses of pharmaco-EEG and pharmacokinetic-pharmacodynamic modeling in the clinical scenario
    Barbanoj, MJ
    Valle, M
    Kulisevsky, J
    Pérez, V
    Gambús, P
    METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY, 2002, 24 : 139 - 144
  • [32] PRELIMINARY PHARMACOKINETIC-PHARMACODYNAMIC MODELING OF THEOPHYLLINE AND ITS POSSIBLE CLINICAL IMPLICATIONS
    HEGER, RJ
    BRADBERRY, JC
    HOOVER, D
    VADIEI, K
    ODELL, D
    YOUNG, D
    DRUG INTELLIGENCE & CLINICAL PHARMACY, 1984, 18 (06): : 505 - 505
  • [33] Clinical pharmacokinetic-pharmacodynamic analyses: a critical element for developing antibacterial agents
    Bhavnani, Sujata M.
    Hammel, Jeffrey P.
    CURRENT OPINION IN PHARMACOLOGY, 2017, 36 : 124 - 129
  • [34] Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response
    Bender, Brendan C.
    Schindler, Emilie
    Friberg, Lena E.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 79 (01) : 56 - 71
  • [35] Pharmacokinetic-pharmacodynamic relationships describing the efficacy of oritavancin in patients with Staphylococcus aureus bacteremia
    Bhavnani, SM
    Passarell, JA
    Owen, JS
    Loutit, JS
    Porter, SB
    Ambrose, PG
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (03) : 994 - 1000
  • [36] Pharmacokinetic-pharmacodynamic population modelling in paediatric anaesthesia and its clinical translation
    Morse, James D.
    Hannam, Jacqueline
    Anderson, Brian J.
    CURRENT OPINION IN ANESTHESIOLOGY, 2019, 32 (03) : 353 - 362
  • [37] Exploration of the Pharmacokinetic-Pharmacodynamic Relationships for Fosfomycin Efficacy Using an In Vitro Infection Model
    VanScoy, Brian D.
    McCauley, Jennifer
    Ellis-Grosse, Evelyn J.
    Okusanya, Olanrewaju O.
    Bhavnani, Sujata M.
    Forrest, Alan
    Ambrose, Paul G.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (12) : 7170 - 7177
  • [38] How pharmacokinetic-pharmacodynamic (PK-PD) parameters influence antibiotic use
    Mazzei, T.
    JOURNAL OF CHEMOTHERAPY, 2006, 18 : 19 - 21
  • [39] Vancomycin pharmacokinetic-pharmacodynamic parameters to optimize dosage administration in critically ill children
    Giachetto, Gustavo A.
    Telechea, Hector M.
    Speranza, Noelia
    Oyarzun, Mireille
    Nanni, Luciana
    Menchaca, Amanda
    PEDIATRIC CRITICAL CARE MEDICINE, 2011, 12 (06) : E250 - E254
  • [40] Can pharmacokinetic-pharmacodynamic parameters provide dosing regimens that are less vulnerable to resistance?
    Courvalin, P.
    CLINICAL MICROBIOLOGY AND INFECTION, 2008, 14 (11) : 989 - 994